CG Oncology, Inc. Common stock (CGON)
Automate Your Wheel Strategy on CGON
With Tiblio's Option Bot, you can configure your own wheel strategy including CGON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CGON
- Rev/Share 0.008
- Book/Share 9.2503
- PB 2.7848
- Debt/Equity 0.0015
- CurrentRatio 30.9686
- ROIC -0.1904
- MktCap 1963563986.0
- FreeCF/Share -1.0791
- PFCF -23.883
- PE -27.6013
- Debt/Assets 0.0014
- DivYield 0
- ROE -0.1125
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CGON | JP Morgan | -- | Overweight | -- | $41 | May 2, 2025 |
| Initiation | CGON | Scotiabank | -- | Sector Perform | -- | $23 | April 16, 2025 |
| Initiation | CGON | TD Cowen | -- | Buy | -- | -- | Jan. 7, 2025 |
| Initiation | CGON | RBC Capital Mkts | -- | Outperform | -- | $66 | Sept. 23, 2024 |
| Initiation | CGON | ROTH MKM | -- | Buy | -- | $65 | Aug. 28, 2024 |
News
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Read More
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Negative
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
Read More
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
Published: April 28, 2025 by: Benzinga
Sentiment: Positive
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
Read More
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
Read More
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
Published: April 02, 2025 by: Seeking Alpha
Sentiment: Positive
CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON's enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.
Read More
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Read More
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET.
Read More
About CG Oncology, Inc. Common stock (CGON)
- IPO Date
- Website https://cgoncology.com
- Industry Biotechnology
- CEO Mr. Arthur Kuan
- Employees 113